Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing

Tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib are effective against lung adenocarcinomas harboring epidermal growth factor receptor (EGFR) mutations. However, cancer cells can develop resistance to these agents with prolonged exposure; in over 50% of cases, this is attributable t...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Park, Mi-Young, Jung, Min Hee, Eo, Eun Young, Kim, Seokjoong, Lee, Sang Hoon, Lee, Yeon Joo, Park, Jong Sun, Cho, Young Jae, Chung, Jin Haeng, Kim, Cheol Hyeon, Il Yoon, Ho, Lee, Jae Ho, Lee, Choon-Taek
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5482658/
https://ncbi.nlm.nih.gov/pubmed/28422737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16752
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires